Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma:A Prospective Study Within the Nationwide Netherlands Cancer Registry
Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, d... Mehr ...
Verfasser: |
Wester, Ruth
Dinmohamed, Avinash G.
van der Holt, Bronno
Zweegman, Sonja
Minnema, Monique
Croockewit, Sandra
Levin, Mark-David
Libourel, Eduard
de Waal, Esther
Sonneveld, Pieter
Cornelissen, Jan
Blijlevens, Nicole
Broijl, Annemiek |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2022 |
Reihe/Periodikum: |
Wester , R , Dinmohamed , A G , van der Holt , B , Zweegman , S , Minnema , M , Croockewit , S , Levin , M-D , Libourel , E , de Waal , E , Sonneveld , P , Cornelissen , J , Blijlevens , N & Broijl , A 2022 , ' Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma : A Prospective Study Within the Nationwide Netherlands Cancer Registry ' , HemaSphere , vol. 6 , no. 2 , pp. E683 . https://doi.org/10.1097/HS9.0000000000000683 , https://doi.org/10.1097/HS9.0000000000000683 |
Schlagwörter: |
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
/ name=SDG 3 - Good Health and Well-being |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-27226059 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://pure.eur.nl/en/publications/f7dae1a7-86ca-48de-b1ba-e5e27cdbe595 |